Comparing the current results to its competitors, Tectonic Therapeutic Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 129.27 %, recorded in the same quarter.
Tectonic Therapeutic Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, characterized by rapid technological advancements and a strong focus on intellectual property. It faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic, governmental, and private research institutions worldwide. Competitors often possess greater financial resources and expertise in drug development and commercialization. Smaller or early-stage companies may also be competitors, particularly through collaborations with larger firms. Specific competitors include AstraZeneca, which is conducting a Phase 2b trial for a small molecule relaxin targeting chronic heart failure (both HFpEF and HFrEF). In the hereditary hemorrhagic telangiectasia (HHT) space, Vaderis, Terremoto, and Atavistik are engaged in development efforts.
May 17, 2025
Tectonic Therapeutic, Inc. (NASDAQ: TECX) recently shared the complete results from Part A of their Phase 1b clinical trial of TX45, a potential treatment for Group 2 Pulmonary Hypertension in patients with Heart Failure with preserved Ejection Fraction (HFpEF). These results, which represent a significant milestone for Tectonic s leading asset a long-acting relaxin therapy were presented in a late-breaking session at the European Society of Cardiology (ESC) Heart Failure 2025 Congress in Belgrade, Serbia. Clinical Trial Results The Phase 1b trial results of TX45, involving a full cohort of 19 patients, add compelling insights into the management of Group 2 Pulmonary Hypertension in HFpEF. This follows previ...
November 11, 2024
Tectonic Therapeutics Makes Strides in Heart Failure Treatment with Promising TX45 Phase 1a Results On November 11, 2024, Tectonic Therapeutics, a clinical-stage biotechnology firm based in Watertown, Massachusetts, unveiled positive results from a Phase 1a trial for its lead therapeutic candidate, TX45. This innovative drug, formulated as a long-acting Fc-relaxin fusion protein, aims to provide groundbreaking treatment options for patients suffering from pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Key Highlights of the Announcement1. Promising Results : The company reported favorable topline outcomes from the Phase 1a clinical trial, an important miles...
Beyond Air Inc is a company that operates on a business model focused on developing and commercializing medical devices for the treatment of respiratory conditions using innovative nitric oxide technology.
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.
Jasper Therapeutics Inc operates in the biotechnology industry, focusing on developing stem cell-based therapies for hematopoietic and immune system disorders. Their business model involves utilizing innovative stem cell technologies and partnerships within the medical community to advance their research and bring potential treatments to patients in need.
Sources:
Tectonic Therapeutic Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tectonic Therapeutic Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
